Gan & Lee(SH:603087) Guotou Securities·2025-10-31 02:11Investment Rating - The investment rating for the company is "Buy-A" with a target price of 84.00 CNY for the next six months [7][10]. Core Insights - The company has achieved significant revenue and net profit growth in the first three quarters of 2025, with revenues of 30.47 billion CNY and a net profit of 8.18 billion CNY, representing year-on-year increases of 35.73% and 61.32% respectively [2][3]. - Domestic sales revenue reached 26.90 billion CNY, up 44.01%, while international sales revenue was 3.53 billion CNY, up 45.52%, driven by price increases following domestic insulin procurement and expanding international sales [2][4]. - The company is actively participating in domestic insulin procurement, leading to a continuous increase in insulin formulation sales, with domestic formulation revenue growing by 45.6% year-on-year [3]. - The company is advancing its globalization strategy, signing a 10-year technical transfer and supply agreement with Brazil, with a cumulative order amount expected to exceed 30 billion CNY [4]. - The company's pipeline includes promising insulin formulations, with GZR4 in Phase III clinical trials domestically and Phase I in Europe and the US, positioning it as a potential cornerstone drug for diabetes treatment [5]. Financial Performance - The company forecasts net profits of 11.09 billion CNY, 14.32 billion CNY, and 15.95 billion CNY for 2025, 2026, and 2027, respectively, with growth rates of 80.4%, 29.1%, and 11.4% [10]. - The projected earnings per share (EPS) for 2026 is 2.40 CNY, with a price-to-earnings (PE) ratio of 35 times [10]. - The company's total market capitalization is approximately 41.75 billion CNY, with a circulating market capitalization of about 38.99 billion CNY [7].